EDAP TMS announces first pancreatic cancer patient treated with HIFU tech

EDAP TMS (EDAP) announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Leon Berard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound, HIFU, technology for the treatment of pancreatic tumors. “We are proud to share this noteworthy achievement as part of our on-going commitment to innovation and improving the lives of patients across a diverse spectrum of disease states,” said Ryan Rhodes, Chief Executive Officer of EDAP. “This first treatment milestone is the result of a strong collaboration between our product and clinical development teams as well as our strategic research and clinical partnerships. This demonstrates our on-going technical and clinical leadership in applying focused ultrasound therapy in areas of significant unmet need.”